Beyond Lifestyle: A Practical Guide to Liver-Directed Therapy for MASH

Dr Mazen Noureddin explains how PCPs can identify MASH patients with fibrosis who may benefit from liver-directed therapy, while maintaining lifestyle and metabolic care.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-masld-s1-ep5-2026a1000aax. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis https://reference.medscape.com/cc2/p10/global-consensus-recommendations-metabolic-dysfunction-2025a1000iy5#1

Steatotic Liver Disease (SLD) https://emedicine.medscape.com/article/175472-overview

Hepatic Thyroid Hormone Receptor-β Signalling: Mechanisms and Recent Advancements in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/39658733/

Cardiovascular-Kidney-Metabolic (CKM) Syndrome https://emedicine.medscape.com/article/165124-overview

Diagnostic Performance of Circulating Biomarkers for Non-Alcoholic Steatohepatitis https://pubmed.ncbi.nlm.nih.gov/37679433/

The Role of Fibroscan in the Era of Metabolic (Dysfunction)-Associated Fatty Liver Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10209980/

Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review https://pubmed.ncbi.nlm.nih.gov/37632072/

FIB-4 for Noninvasive Diagnosis of Hepatic Fibrosis https://reference.medscape.com/calculator/326/fib-4-for-noninvasive-diagnosis-of-hepatic-fibrosis

MELD 3.0 in Advanced Chronic Liver Disease https://pubmed.ncbi.nlm.nih.gov/37751367/

The Enhanced Liver Fibrosis (ELF) Test in Diagnosis and Management of Liver Fibrosis https://pubmed.ncbi.nlm.nih.gov/30526098/

Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial https://pubmed.ncbi.nlm.nih.gov/41127972/

Resmetirom Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease: October 2024 Updates to AASLD Practice Guidance https://pubmed.ncbi.nlm.nih.gov/39422487/

Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis https://pubmed.ncbi.nlm.nih.gov/39038768/

Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations https://pubmed.ncbi.nlm.nih.gov/42483637/

FDA Accelerated Approval Program https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approval-program

A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH https://pubmed.ncbi.nlm.nih.gov/34670042/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.